Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00801242
• Other study ID #: FE200486 CS29
• Secondary ID: 2008-003931-19
• Status: Completed
• Phase: Phase 3
• First received: December 2, 2008
• Last updated: September 2, 2014
• Start date: December 2008
• Est. completion date: July 2013

Study information

• Verified date: September 2014
• Source: Ferring Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: National Consultative Ethics Committee for Health and Life SciencesBelgium: Federal Agency for Medicinal Products and Health ProductsBelgium: Institutional Review BoardSpain: Spanish Agency of MedicinesSpain: Comité Ético de Investigación ClínicaItaly: Ethics CommitteeItaly: National Monitoring Centre for Clinical Trials - Ministry of HealthItaly: The Italian Medicines AgencyNetherlands: Medicines Evaluation Board (MEB)Netherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)Germany: Federal Institute for Drugs and Medical DevicesGermany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.

Description:

The participants received one or more treatment cycles of seven monthly degarelix doses during the induction period(s). The off-treatment period(s) started when prostate-specific antigen (PSA) ≤4 ng/mL and lasted up to 24 months based on PSA levels. A visit was scheduled on a monthly basis during the induction treatment periods, and every two months during the off-treatment periods. During the off-treatment periods, degarelix treatment was re-initiated when PSA >4 ng/mL. The maximum of degarelix IAD treatment cycles that a participant could receive was limited to three.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: July 2013
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has given written informed consent before any trial-related activity is performed. A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient.

• Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), and is in need of androgen deprivation treatment.

• Patients with Locally Advanced or Metastatic Prostate Cancer - Screening PSA level (measured at a central laboratory) must be >4 ng/mL and =50 ng/mL.

• Patients with Localised Prostate Cancer or Patients with Previous Therapy with Curative Intention and a Rising PSA - PSA doubling time (based on patient records at the trial site) must be <24 months. There is no minimum PSA level required and the maximum PSA must be =50 ng/mL.

• Is a male patient aged 18 years or older.

• Has an Eastern Cooperative Oncology Group score of =2.

• Has a life expectancy of at least 24 months.

Exclusion Criteria:

• Has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation, including gonadotropin releasing hormone (GnRH) receptor agonists, GnRH antagonists, anti-androgens, 5-alpha reductase inhibitors and estrogens). However, for patients having undergone prostatectomy or radiotherapy with curative intention, then neoadjuvant/adjuvant hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to Screening Visit.

• Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.

• Has a history of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria and/or angioedema.

• Has hypersensitivity towards any component of the investigational medicinal product.

• Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin.

• Has a known or suspected clinically significant liver and/or biliary disease.

• Has a history of or risk factors for Torsades de Pointes

• At time of inclusion receives concomitant medications that might prolong the QT interval.

• Has any clinically significant laboratory abnormalities which in the judgment of the investigator would affect the patient's health or the outcome of the trial.

• Has a clinically significant disorder (other than prostate cancer) including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, which may affect the patient's health or the outcome of the trial as judged by the investigator.

• Has severe kidney failure (creatinine clearance <30 mL/min), based on the serum creatinine value at Screening Visit and calculated by Cockcroft-Gault algorithm (only valid in France).

• Has a mental incapacity or language barriers precluding adequate understanding or co operation.

• Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial.

• Has previously participated in any degarelix trial

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Degarelix 240 mg / 80 mg
For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.

Locations

Country	Name	City	State
Belgium	Hospital St Jan Brugge	Brugge
Belgium	Erasme Hospital, University Clinics of Brussels	Brussels
Belgium	University Hospîtal St-Luc	Brussels
Belgium	University Hospitals Leuven	Leuven
France	CHU Hôpital Sud	AMIENS cedex 1
France	Hôpital Pellegrin	BORDEAUX cedex
France	Centre Hospitalier René Dubos	CERGY PONTOISE cedex
France	Hôpital Gabriel Montpied	CLERMONT-FERRAND cedex 1
France	Hôpital Henri Mondor	Creteil
France	Hôpital Claude Huriez	LILLE cedex
France	Hôpital de la Conception	MARSEILLE cedex 05
France	Clinique Beausoleil	Montpellier
France	CHU Hôtel-Dieu	NANTES cedex 1
France	Hôpital Pasteur	NICE cedex 1
France	CHU Bichat	Paris
France	CHU Pitié Salpétrière	Paris
France	Hôpital Saint Louis	Paris
France	Hôpital Cochin	PARIS cedex 14
France	Hôpital Tenon	PARIS cedex 20
France	Centre Hospitalier Lyon Sud	Pierre Benite
France	CHU Le Milétrie	Poitiers
France	Hôpital Pontchaillou	RENNES cedex
France	Hôpitaux Universitaires de Strasbourg	STRASBOURG cedex
France	Hôpital de Rangueil	TOULOUSE cedex 9
Germany	Gemeinschaftspraxis Dres. Böhle, Rohde	Bad Schwartau
Germany	Universitätsklinikum Düsseldorf	Düsseldorf
Germany	Gemeinschaftspraxis - Tagesklinik Dres. Rulf, Langhorst	Erkrath
Germany	Urologische Gemeinschaftspraxis	Kempen
Germany	Gemeinschaftspraxis Dres. Rudolph, Wörner	Kirchheim
Germany	Facharzt für Urologie	Rosenheim
Germany	Eberhard-Kars-Universität Tübingen	Tübingen
Germany	Facharzt für Urologie	Wertingen
Germany	Praxisgemeinschaft f. Onkologie & Urologie	Wilhelmshaven
Germany	Praxis für Urologie	Zwickau
Italy	Azienda Ospedaliera S. Giuseppe Moscati	Avellino
Italy	Università degli Studi di Firenze	Bagno a Ripoli (FI)
Italy	Azienda Policlinico Universitario G. Martino	Messina
Italy	Ospedale S. Raffaele	Milano
Italy	Università degli Studi di Padova	Padova
Italy	Policlinico Univ. Agostino Gemelli	Roma
Netherlands	Twenteborg Ziekenhuis	Almelo
Netherlands	Universitair Medisch Centrum Groningen	Groningen
Netherlands	Atrium MC Kerkrade	Kerkrade
Netherlands	Maatschap Urologie-Diaconessenhuis Leiden	Leiden
Netherlands	UMC St.Radboud	Nijmegen
Spain	Complexo Hospitalario Universitario A Coruña (CHUAC)	A Coruña
Spain	Hospital Universitario Principe de Asturias	Alcalá de Henares, Madrid
Spain	Hospital Universitario Vall d'Hebron	Barcelona
Spain	Hospital Virgen de las Nieves	Granada
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Corporacio Sanitaria Parc Tauli	Sabadell
Spain	Instituto Valenciano de Oncologia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Ferring Pharmaceuticals

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7 Monthly Injections of Degarelix Induction Treatment	Blood samples for analyses of serum PSA levels were collected at the Screening Visit, and every two months during the course of the trial, and at the End-of-Trial Visit. Analyses were performed using chemiluminometric immunoassay.	Up to 24 months after end of induction period	No
Secondary	Percentage Change in PSA Serum Levels From Baseline to the Last Visit of the Induction Period During the First Cycle of IAD		7 months	No
Secondary	Median and Between Participant Variability of Time to Return to Testosterone >0.5 ng/mL (Above Castration Level) During the First Cycle of IAD After 7 Monthly Injections of Degarelix Induction Treatment	Blood samples for analyses of serum testosterone levels were collected at the Screening Visit, Month 4 and 7 of the induction period of Cycle 1 and the corresponding visits of any additional treatment cycles, every two months during the off-treatment period(s), and at the End-of-Trial Visit. Analyses were performed using Liquid-Liquid Extraction and Liquid Chromatography-Mass Spectrometry/Mass Spectrometry.	Up to 24 months after end of induction period	No
Secondary	Number of Participants With Testosterone =0.5 ng/mL at the Last Visit of the Induction Period During the First Cycle of IAD		7 months	No
Secondary	Quality of Life, as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Module (EORTC QLQ-PR25), During the Induction Treatment and Off-treatment Periods During the First Cycle of IAD	The EORTC QLQ-PR25 employs a modular approach towards assessing cancer patients´ health-related Quality of Life (QoL) and assesses urinary, bowel, and sexual symptoms and functioning, and the side-effects of hormonal treatment. It consists of 25 questions distributed on six domains (number of items per domain, ranges from x to y: urinary symptoms (8, 0-100), bother due to use of incontinence aid (1, 0-100), bowel symptoms (4, 0-100), hormonal treatment-related symptoms (6, 0-100), sexual activity (2, 0-100), and sexual functioning (4, 0-100). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).	Up to 31 months	No
Secondary	Sexual Function, as Assessed by the International Index of Erectile Function (IIEF) Scale, During the Induction Treatment and Off-treatment Periods During the First Cycle of IAD	The IIEF scale addresses the relevant domains of male sexual function (i.e. erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction). The IIEF scale is psychometrically sound, and has been linguistically validated in multiple languages. The IIEF scale demonstrates the sensitivity and specificity for detecting treatment-related changes in patients with erectile dysfunction. It consists of the following domains (number of items per domain; ranges from x to y: erectile function (6; 1-30), orgasmic function (2; 0-10), sexual desire (2; 2-10), intercourse satisfaction (3; 0-15) and overall satisfaction (2; 2-10). For all domains, a higher score represents a better sexual function.	Up to 31 months	No
Secondary	Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight During One or More Cycles of Degarelix IAD Treatment	This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value during the trial.	Up to 3 x 31 months	No
Secondary	Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables During One or More Cycles of Degarelix IAD Treatment	This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value during the trial. ULN=Upper limit of normal.	Up to 3 x 31 months	No